Royce & Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Royce & Associates’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-37,500	Closed	-$3.13M	–	876
2024 Q4	$3.13M	Hold	37,500	–	–	0.03%	558
2024 Q3	$2.74M	Hold	37,500	–	–	0.02%	579
2024 Q2	$2.57M	Buy	37,500 +15,000	+67%	+$1.04M	0.02%	588
2024 Q1	$1.56M	Buy	+22,500	New	+$1.55M	0.01%	665
2018 Q2	–	Sell	-30,000	Closed	-$632K	–	1264
2018 Q1	$632K	Hold	30,000	–	–	﹤0.01%	1028
2017 Q4	$434K	Hold	30,000	–	–	﹤0.01%	1050
2017 Q3	$473K	Hold	30,000	–	–	﹤0.01%	1027
2017 Q2	$373K	Hold	30,000	–	–	﹤0.01%	1052
2017 Q1	$488K	Hold	30,000	–	–	﹤0.01%	1043
2016 Q4	$453K	Buy	30,000 +22,300	+290%	+$315K	﹤0.01%	1015
2016 Q3	$117K	Hold	7,700	–	–	﹤0.01%	1060
2016 Q2	$299K	Buy	+7,700	New	+$277K	﹤0.01%	1027

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Royce & Associates's ITCI Position: Q1 2025 in Review

Royce & Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 37,500 shares — an estimated $3.13M sold.

Royce & Associates first reported a position in ITCI in Q2 2016 and held it in 12 quarters. The position peaked at $3.13M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Royce & Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Royce & Associates sold 37,500 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $3.13M.
Royce & Associates first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 12 quarters.
Royce & Associates's Intra-Cellular Therapies Inc. position peaked at $3.13M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Royce & Associates's 13F filing for Q1 2025, filed 6 May 2025.